In this episode, we explore the role of antiplatelets and anticoagulants in managing acute coronary syndromes (ACS) and during percutaneous coronary intervention (PCI). How many days off clopidogrel, prasugrel, ticagrelor, and cangrelor is advised prior to proceeding to CABG? In patients not undergoing CABG, how does one decide which P2Y12 inhibitor to use? How do glycoprotein IIb/IIIa inhibitors such as abciximab, eptifibatide, and tirofiban prevent platelet aggregation, and in what situations are they indicated in PCI? What anticoagulant can be used in patients who present with ACS but are unable to take heparin due to allergy, religious reasons, or heparin-induced thrombocytopenia? Tune in for answers to these questions.

Difficulty Level: Easy

You are listening to Hu Said: Cardiology Board Review Series (2024-2025 Season)

Please subscribe, rate, and support the channel! Ads help keep materials free for everyone.

More MedEd resources available at ⁠www.rueyhu.com⁠

Updates at Twitter/X: ⁠@Ruey_Hu⁠